Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow JUPITER NEUROSCIENCES, INC.

Get SEC filing alerts via email and in your feed for JUPITER NEUROSCIENCES, INC.

JUNS

JUPITER NEUROSCIENCES, INC.

About JUPITER NEUROSCIENCES, INC.

Jupiter Neurosciences is a clinical-stage biotech focused on developing therapies for neuroinflammatory and neurodegenerative diseases. Its flagship product, JOTROL, is an enhanced oral resveratrol formulation targeting conditions like Parkinson’s, Alzheimer’s, rare genetic disorders, and mitochondrial diseases. The company leverages proprietary technology, strategic partnerships, and a global licensing approach to advance clinical trials and commercialize natural, bioavailable treatments for unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from JUPITER NEUROSCIENCES, INC.

1
1
JUPITER NEUROSCIENCES, INC. Jupiter Neurosciences Reports $18,652 Revenue and $2.06M Net Loss in Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
JUPITER NEUROSCIENCES, INC. Jupiter Neurosciences Reports $21,796 Revenue and $8.6 Million Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
JUPITER NEUROSCIENCES, INC. Jupiter Neurosciences Reports $6.07 Million Net Loss and Financial Challenges in Latest Filing

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
JUPITER NEUROSCIENCES, INC. Jupiter Neurosciences Reports $3.78 Million Net Loss and Increased Expenses in Latest Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
JUPITER NEUROSCIENCES, INC. Jupiter Neurosciences Reports $1.53 Million Net Loss in Q1 2025 Amid Rising Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments